This is a preview of subscription content, log in via an institution to check access.
Notes
funded by Bayer Pharma AG
Reference
Monreal M, et al. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thrombosis and Haemostasis 110: No. 5, 22 Aug 2013. Available from: URL: http://dx.doi.org/10.1160/TH12-12-0919
Rights and permissions
About this article
Cite this article
Rivaroxaban cost effective for VTE prevention in TKR and THR. PharmacoEcon Outcomes News 687, 9 (2013). https://doi.org/10.1007/s40274-013-0728-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0728-4